I6T-MC-AMAH

Phase 3

Completed

• Conditions: Psoriasis

• Registration Number: JPRN-jRCT2080224141
• Lead Sponsor: Eli Lilly Japan K.K.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-11-13
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: completed
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Participant must have completed the last visit of an eligible study period of originating study.
- Participant must be willing to follow the birth control measures during and after study treatment if woman of childbearing potential.

Exclusion Criteria

- Participant must not have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disease or abnormal lab results, that the study investigator thinks makes it unsafe or inappropriate for the participant to participate in this study.
- Participant must not have stopped taking mirikizumab during a previous study if the study investigator does not think the participant should resume taking mirikizumab.

Study & Design

• Study Type: Interventional
• Study Design: Not specified